Chemotherapy after surgery for low-risk stomach or esophagus cancer
Part of Cancer, Digestive system clinical trials.
This trial compares standard chemotherapy after surgery with a reduced course of chemotherapy for people with a certain type of stomach or esophagus cancer that has a low chance of returning. It aims to see if a shorter treatment works just as well and causes fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with adenocarcinoma of the stomach, esophagus, or the area where they meet, and it has not spread to other parts of the body.
- You have already completed chemotherapy before surgery (a regimen called FLOT) and had surgery to remove the tumor with clean margins (R0 resection).
- Your cancer was found to have a low risk of coming back based on specific lymph node and tumor characteristics (no cancer in lymph nodes, and the tumor response to chemotherapy was favorable).
- You are in good physical condition (ECOG performance status 0-1) and well enough to receive additional chemotherapy.
- Your organ function (kidney, liver, blood counts) is within acceptable limits.
- You have signed an informed consent form and are willing to follow study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations given before surgery for stomach cancer that has not spread. The goal is to see which treatment works better and to shrink the tumor before removal.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial studies whether adding chemotherapy after surgery for esophageal squamous cell cancer can reduce the chance the cancer returns. It focuses on people whose surgery removed cancerous lymph nodes and who are healthy enough to tolerate chemotherapy.
This study tests whether adding radiation or surgery to chemotherapy can improve outcomes for people whose esophageal or stomach cancer has spread to only a few places. If your cancer is “oligometastatic” (up to 3 spots), the trial helps doctors see which approach gives the best control.
This trial tests whether skipping chemotherapy after surgery is safe and effective for some patients with gastric cancer. If your tumor responded very well or very poorly to the pre-surgery chemotherapy, you might be able to avoid more chemo.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
Hear when a new Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.